These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 7511683)
1. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. Ramarathinam L; Castle M; Wu Y; Liu Y J Exp Med; 1994 Apr; 179(4):1205-14. PubMed ID: 7511683 [TBL] [Abstract][Full Text] [Related]
2. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency. Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574 [TBL] [Abstract][Full Text] [Related]
3. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors. Zheng P; Sarma S; Guo Y; Liu Y Cancer Res; 1999 Jul; 59(14):3461-7. PubMed ID: 10416611 [TBL] [Abstract][Full Text] [Related]
4. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. Li Y; McGowan P; Hellström I; Hellström KE; Chen L J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929 [TBL] [Abstract][Full Text] [Related]
5. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. Azuma M; Cayabyab M; Buck D; Phillips JH; Lanier LL J Exp Med; 1992 Feb; 175(2):353-60. PubMed ID: 1370679 [TBL] [Abstract][Full Text] [Related]
6. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. Harding FA; Allison JP J Exp Med; 1993 Jun; 177(6):1791-6. PubMed ID: 7684435 [TBL] [Abstract][Full Text] [Related]
7. Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro. Imro MA; Dellabona P; Manici S; Heltai S; Consogno G; Bellone M; Rugarli C; Protti MP Hum Gene Ther; 1998 Jun; 9(9):1335-44. PubMed ID: 9650618 [TBL] [Abstract][Full Text] [Related]
9. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites. Kobori H; Hashiguchi M; Piao J; Kato M; Ritprajak P; Azuma M Immunology; 2010 Jul; 130(3):363-73. PubMed ID: 20141543 [TBL] [Abstract][Full Text] [Related]
10. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation. Wang YC; Zhu L; McHugh R; Graham SD; Hillyer CD; Dillehay D; Sell KW; Selvaraj P J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):1-8. PubMed ID: 9147700 [TBL] [Abstract][Full Text] [Related]
11. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties. Boyer MW; Vallera DA; Taylor PA; Gray GS; Katsanis E; Gorden K; Orchard PJ; Blazar BR Blood; 1997 May; 89(9):3477-85. PubMed ID: 9129056 [TBL] [Abstract][Full Text] [Related]
12. Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells. Liu Y; Qureshi M; Xiang J Cancer Biother Radiopharm; 2002 Feb; 17(1):11-8. PubMed ID: 11915168 [TBL] [Abstract][Full Text] [Related]
13. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. Johnston JV; Malacko AR; Mizuno MT; McGowan P; Hellström I; Hellström KE; Marquardt H; Chen L J Exp Med; 1996 Mar; 183(3):791-800. PubMed ID: 8642283 [TBL] [Abstract][Full Text] [Related]
14. A mechanism for selective recruitment of CD8 T cells into B7-1-transfected plasmacytoma: role of macrophage-inflammatory protein 1alpha. Maric M; Chen L; Sherry B; Liu Y J Immunol; 1997 Jul; 159(1):360-8. PubMed ID: 9200474 [TBL] [Abstract][Full Text] [Related]
15. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines. Fenton RG; Turcovski-Corrales SM; Taub DD J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360 [TBL] [Abstract][Full Text] [Related]
16. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma. Prell RA; Kerkvliet NI J Immunol; 1997 Mar; 158(6):2695-703. PubMed ID: 9058803 [TBL] [Abstract][Full Text] [Related]
17. Vaccine of engineered tumor cells secreting stromal cell-derived factor-1 induces T-cell dependent antitumor responses. Shi M; Hao S; Su L; Zhang X; Yuan J; Guo X; Zheng C; Xiang J Cancer Biother Radiopharm; 2005 Aug; 20(4):401-9. PubMed ID: 16114988 [TBL] [Abstract][Full Text] [Related]
18. T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Döhring C; Angman L; Spagnoli G; Lanzavecchia A Int J Cancer; 1994 Jun; 57(5):754-9. PubMed ID: 7515023 [TBL] [Abstract][Full Text] [Related]
19. B7/BB1 provides an important costimulatory signal for CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus (SLE). Sfikakis PP; Oglesby R; Sfikakis P; Tsokos GC Clin Exp Immunol; 1994 Apr; 96(1):8-14. PubMed ID: 7512010 [TBL] [Abstract][Full Text] [Related]
20. CD4-CD8- T cell receptor alpha beta T cells: generation of an in vitro major histocompatibility complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection. Mieno M; Suto R; Obata Y; Udono H; Takahashi T; Shiku H; Nakayama E J Exp Med; 1991 Jul; 174(1):193-201. PubMed ID: 1905338 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]